

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 09/776,479

ATTY. DOCKET NO.: C1037.70013US00

FILING DATE: February 2, 2001

CONFIRMATION NO.: 7139

APPLICANT: Robert L. Bratzler et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		6,086,898		DeKruyff et al.	07-11-2000
		6,610,308		Haensler et al.	08-26-2003
		7,208,478	B2	Carson et al.	04-24-2007
		7,223,398	B1	Tuck et al.	05-29-2007
		7,354,711	B2	Macfarlane	04-08-2008
		7,402,572	B2	Krieg et al.	07-22-2008
		7,410,975	B2	Lipford et al.	08-12-2008
		2003-0186921	A1	Carson et al.	10-02-2003
		2008-0009455	A9	Krieg et al.	01-10-2008
		2008-0026011	A1	Krieg et al.	01-31-2008
		2008-0031936	A1	Krieg et al.	02-07-2008
		2008-0045473	A1	Uhlmann et al.	02-21-2008
		2008-0113929	A1	Lipford et al.	05-15-2008
		2008-0226649	A1	Schetter et al.	09-18-2008

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
		EP	1 671 646	A2	Dynavax Technologies Corporation	06-21-2006	
		WO	99/62923	A2	Dynavax Technologies Corporation	12-09-1999	
		WO	01/35991	A2	Dynavax Technologies Corporation	05-25-2001	
		WO	01/45750	A1	The Regents of the University of California	06-28-2001	
		WO	2004/041183	A2	The Regents of the University of California	05-21-2004	
		WO	2006/096497	A2	Dynavax Technologies Corporation	09-14-2006	
		WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
		WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
		WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	
		WO	2008/068638	A2	Coley Pharmaceutical GMBH	06-12-2008	

EXAMINER:

/N. M. Minnifield/ (02/12/2009)

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 09/776,479

ATTY. DOCKET NO.: C1037.70013US00

FILING DATE: February 2, 2001

CONFIRMATION NO.: 7139

APPLICANT: Robert L. Bratzler et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

NOV 24 2008

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
Press Release, June 2006, "Cytos Biotechnology updates on development of allergy vaccine".	
CHISHOLM et al., Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol. 2004 Mar;113(3):448-54.	
CHO et al., Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am J Respir Cell Mol Biol. 2004 May;30(5):651-61. Epub 2003 Nov 14.	
CRETICOS et al., New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA. Immunol Allergy Clin North Am. 2004 Nov;24(4):569-81.	
FANUCCHI et al., Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med. 2004 Dec 1;170(11):1553-7. Epub 2004 Aug 11.	
HESSEL et al., Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J Exp Med. 2005 Dec 5;202(11):1563-73.	
HUSSAIN et al., Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope. 2002 Oct;112(10):1819-26.	
KIPS et al., Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med. 1996 Feb;153(2):535-9.	
KLINE et al., Eat dirt: CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc. 2007 Jul;4(3):283-8. Review.	
KUSSEBI et al., Advances in immunological treatment of allergy. Curr Med Chem. 2003;2:297-308.	
LEE et al., Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice. J Allergy Clin Immunol. 2006 Mar;117(3):597-603. Epub 2006 Jan 27.	
LEWIS et al., Allergy immunotherapy and inhibition of Th2 immune responses: a sufficient strategy? Curr Opin Immunol. 2002 Oct;14(5):644-51.	
LIU et al., CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol. 2003 Jul;4(7):687-93. Epub 2003 May 25.	
RACILA et al., Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J Allergy Clin Immunol. 2005 Dec;116(6):1202-5.	
RHEE et al., Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology. 2004 Sep;113(1):106-13.	
ROY et al., Bacterial DNA in house and farm barn dust. J Allergy Clin Immunol. 2003 Sep;112(3):571-8.	
SANDRASAGRA et al., Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):177-81. Review.	
SANTELIZ et al., Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 2002 Mar;109(3):455-62.	
STRIETER, What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair,	

EXAMINER:

/N. M. Minnifield/ (02/12/2009)

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 09/776,479

ATTY. DOCKET NO.: C1037.70013US00

FILING DATE: February 2, 2001

CONFIRMATION NO.: 7139

APPLICANT: Robert L. Bratzler et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet 3 of 3

NOV 24 2008

and fibrosis. Proc Am Thorac Soc. 2008 Apr 15;5(3):305-10.

VOLLMER, TLR9 in health and disease. Int Rev Immunol. 2006 May-Aug;25(3-4):155-81.

YOUN et al., Immunostimulatory DNA reverses established allergen-induced airway remodeling. J Immunol. 2004 Dec 15;173(12):7556-64.

ZHU et al., Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Int Immunopharmacol. 2004 Jul;4(7):851-62.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:
/N. M. Minnifield/ (02/12/2009)

DATE CONSIDERED:

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/